- Report
- February 2025
- 200 Pages
Global
From €4240EUR$4,490USD£3,608GBP
- Report
- February 2025
- 200 Pages
Global
From €4240EUR$4,490USD£3,608GBP
- Report
- March 2025
- 150 Pages
Global
From €4580EUR$4,850USD£3,898GBP
- Report
- July 2024
- 150 Pages
Global
From €3541EUR$3,750USD£3,014GBP
- Report
- May 2024
- 185 Pages
Global
From €4250EUR$4,500USD£3,616GBP
- Report
- March 2025
- 150 Pages
Global
From €4580EUR$4,850USD£3,898GBP
- Report
- April 2023
- 175 Pages
Global
From €5571EUR$5,899USD£4,741GBP
- Report
- September 2023
- 236 Pages
Global
From €5619EUR$5,950USD£4,782GBP
- Report
- April 2021
China
From €2455EUR$2,600USD£2,090GBP
- Report
- February 2022
- 180 Pages
Global
From €4203EUR$4,450USD£3,576GBP
- Report
- February 2024
- 118 Pages
Global
From €3500EUR$3,970USD£3,083GBP
Meropenem is an antibiotic used to treat a wide range of bacterial infections. It belongs to a class of antibiotics known as carbapenems, which are used to treat infections caused by Gram-negative bacteria. Meropenem is effective against a broad range of bacteria, including those that are resistant to other antibiotics. It is commonly used to treat infections of the urinary tract, skin, and soft tissue, as well as pneumonia and meningitis. Meropenem is also used to treat infections caused by multi-drug resistant bacteria.
Meropenem is available in both intravenous and oral formulations. It is typically administered as an intravenous infusion over a period of 30 minutes to one hour. The oral formulation is taken twice daily. Meropenem is generally well tolerated, with the most common side effects being nausea, vomiting, and diarrhea.
The Meropenem market is highly competitive, with several major players offering a range of products. These include Merck & Co., Pfizer, GlaxoSmithKline, AstraZeneca, and Sanofi. Other companies in the market include Allergan, Daiichi Sankyo, and Teva Pharmaceuticals. Show Less Read more